ArticleCureus2025
Refractory Digital Ulcers in Systemic Sclerosis Sine Scleroderma Associated With Antiphospholipid Syndrome: A Case-Based Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital ulcers (DUs) are a severe manifestation of the vasculopathy underlying systemic sclerosis (SSc). In cases refractory to treatment, the presence of other modifiable causes of vasculopathy, such as antiphospholipid syndrome (APS), should be considered, although its diagnosis in patients with systemic sclerosis sine scleroderma (ssSSc) is exceedingly rare. We report the case of a 20-year-old Caucasian female with ssSSc, who presented with Raynaud's phenomenon (RP), recurrent DU, telangiectasias, inflammatory arthralgias, dyspepsia, and epigastric pain, in the absence of skin thickening. Laboratory investigation revealed a high-titre antinuclear antibody (ANA; 1:2560) with an anti-centromere pattern, and positivity for both anti-centromere antibodies (ACA) and anti-Ro-52 antibodies. Nailfold capillaroscopy showed an early scleroderma pattern. Despite optimized vasodilatory therapy, including calcium channel blockers, phosphodiesterase inhibitors, endothelin receptor antagonists, and regular iloprost infusions, the patient continued to experience recurrent DU. Following a pulmonary embolism with lingula infarction, anticoagulation was initiated, resulting in complete healing of the DU within two months and no subsequent thrombotic events. Repeat testing confirmed persistent positivity for lupus anticoagulant (LA) and anti-β2-glycoprotein I (anti-β2GPI) IgG more than 12 weeks apart, establishing the diagnosis of secondary APS. To our knowledge, this is the fourth reported case of ssSSc with secondary APS, and the first presenting with recurrent DU and pulmonary embolism, highlighting the rarity of this association and the importance of considering APS in SSc patients with refractory DU. The association between SSc and APS remains poorly understood, and further research is needed to clarify the underlying mechanisms and guide optimal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.